Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
Public ClinicalTrials.gov record NCT03054428. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of the study was to demonstrate the efficacy of dupilumab as a monotherapy in participants ≥12 years to \<18 years of age with moderate-to-severe atopic dermatitis (AD). The secondary objective of the study was to assess the safety of dupilumab as a monotherapy in participants ≥12 years to \<18 years of age with moderate-to-severe AD.
Study identification
- NCT ID
- NCT03054428
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 251 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 21, 2017 (Actual)
- Primary completion
- Apr 4, 2018 (Actual)
- Completion
- Jun 5, 2018 (Actual)
- Last update posted
- Jul 23, 2019
2017 – 2018
United States locations
- U.S. sites
- 36
- U.S. states
- 23
- U.S. cities
- 34
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Regeneron Investigational Site | Birmingham | Alabama | 35209 | — |
| Regeneron Investigational Site | Gilbert | Arizona | 85234 | — |
| Regeneron Investigational Site | Bakersfield | California | 93309 | — |
| Regeneron Investigational Site | Long Beach | California | 90808 | — |
| Regeneron Investigational Site | Rolling Hills Estates | California | 90274 | — |
| Regeneron Investigational Site | San Diego | California | 92123 | — |
| Regeneron Investigational Site | Santa Rosa | California | 95403 | — |
| Regeneron Investigational Site | Centennial | Colorado | 80112 | — |
| Regeneron Investigational Site | Denver | Colorado | 80206 | — |
| Regeneron Investigational Site | Washington D.C. | District of Columbia | 20016 | — |
| Regeneron Investigational Site | Tampa | Florida | 33624 | — |
| Regeneron Investigational Site | Macon | Georgia | 31217 | — |
| Regeneron Investigational Site | Sandy Springs | Georgia | 30328 | — |
| Regeneron Investigational Site | Chicago | Illinois | 60611 | — |
| Regeneron Investigational Site | Evansville | Indiana | 47713 | — |
| Regeneron Investigational Site | Indianapolis | Indiana | 46256 | — |
| Regeneron Investigational Site | Plainfield | Indiana | 46168 | — |
| Regeneron Investigational Site | Rockville | Maryland | 20850 | — |
| Regeneron Investigational Site | Boston | Massachusetts | 02111 | — |
| Regeneron Investigational Site | Boston | Massachusetts | 02115 | — |
| Regeneron Investigational Site | Plymouth | Minnesota | 55441 | — |
| Regeneron Investigational Site | St Louis | Missouri | 63110 | — |
| Regeneron Investigational Site | Forest Hills | New York | 11375 | — |
| Regeneron Investigational Site | New York | New York | 10029 | — |
| Regeneron Investigational Site | Rochester | New York | 14642 | — |
| Regeneron Investigational Site | Chapel Hill | North Carolina | 27516 | — |
| Regeneron Investigational Site | Bexley | Ohio | 43209 | — |
| Regeneron Investigational Site | Tulsa | Oklahoma | 74136 | — |
| Regeneron Investigational Site | Portland | Oregon | 97223 | — |
| Regeneron Investigational Site | Portland | Oregon | 97239 | — |
| Regeneron Investigational Site | Philadelphia | Pennsylvania | 19104 | — |
| Regeneron Investigational Site | Charleston | South Carolina | 29407 | — |
| Regeneron Investigational Site | Bellaire | Texas | 77401 | — |
| Regeneron Investigational Site | San Antonio | Texas | 78218 | — |
| Regeneron Investigational Site | Norfolk | Virginia | 23502 | — |
| Regeneron Investigational Site | Seattle | Washington | 98105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03054428, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 23, 2019 · Synced Nov 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03054428 live on ClinicalTrials.gov.